Q How many slides can I stain with a single kit?
Identify Myeloid Derived Suppressor Cells within the tumor microenvironment
This MDSC 4-plex/5-color kit enables the characterization of myeloid derived suppressor cell populations into M-MDSCs and PMN-MDSCs
This antibody panel consists of the following markers:
For more information about this product please contact Ultivue EMEA contact.emea@ultivue.com
For more information about this product please contact our local distributor in Japan, Cosmo Bio
mail@cosmobio.co.jp, +81 3 5632 9610
For more information about this product please contact our local distributor in South Korea, MDxK
info@mdxk.co.kr, +82 2 578 8848
For more information about this product please contact our local distributor in Singapore, AITbiotech
sales@aitbiotech.com, +65 6778 6822
For more information about this product please contact our local distributor in Taiwan, Bond Biotech.
bond.biotech@gmail.com, +886 4 2358 3959
For more information about this product please contact our local distributor in China, Leica Biosytems China,
+86 400 821 3236
UltiMapper I/O MDSC kit staining non-small cell lung cancer tissue. CD11b (green), CD14 (yellow), CD15 (red), HLA-DR (cyan), and nuclear counterstain (blue).
The UltiMapper I/O MDSC Antibody Panel enables users to identify myeloid-derived suppressor cells (MDSCs). MDSCs are a heterogenous population that grow in response to high levels of inflammation and exhibit levels of immune cell suppression. MDSCs exist mainly in two forms: monocytic MDSCs (M-MDSCs) and polymorphonuclear MDSCs (PMN-MDSCs). These cell types can be characterized based on the co-expression of markers.
Markers | ||||
---|---|---|---|---|
Phenotype | CD11b | CD14 | CD15 | HLA-DR |
Myeloid cell/lymphoid cell | ![]() | |||
Monocyte/Macrophage/Dendritic cell | ![]() | ![]() | ![]() | |
M-MDSC | ![]() | ![]() | (-/low) | |
Granulocyte (neutrophil/eosinophil) | ![]() | ![]() | ![]() | |
PMN-MDSC | ![]() | ![]() | (-/low) | |
Antigen-presenting cell | ![]() |
This multiplex IHC kit enables the spatial identification of single biomarkers and co-expression in cells enabling the observation of several phenotypes. The above is a partial list of the 16 distinct binary phenotypes that this kit can identify. The number of phenotypes increases if binned marker intensities are taken into account (e.g. expression of HLA-DR)
Marker | Main Cell Type | Function |
---|---|---|
CD11b | Myeloid cell | CD11b is primarily expressed on cells of a myeloid lineage. Myeloid cells differentiate into specific cell types such as neutrophils, monocytes, macrophages, and dendritic cells.v |
CD14 | Monocyte | Monocytes are large myeloid cells that can often differentiate into macrophages and dendritic cells. These cells coexpress CD14 and HLA-DR. In the context of MDSCs, M-MDSCs are in a paused state on their path from myeloid to monocytic differentation and express CD14, but lack HLA-DR expression. |
CD15 | Granulocyte | Granulocytes are a type of myeloid cell that are characterized by the presence of granules in the cytoplasm, and have a varying nuclear shape; often termed as polymorphonuclear (PMN) leukocytes. Granucloytes can differentiate into neutrophils (prominent cell type), eosinophils, basophils, and mast cells. In the context of MDSCs, PMN-MDSCs are in a paused state on their development path from myeloid to neutrophil differentiation and express CD15, but lack or weakly express HLA-DR. |
HLA-DR | Antigen-presenting cell | Human leukocyte antigen (HLA) complex encodes the major histocompatibility complex (MHC). HLA-DR is the main isotype of 3 isotype (-DR, -DP, -DQ) responsible for presentation of antigens to T cells and B cells. Often, HLA-DR is used as a marker indicating the presence of antigen-presenting cells (APC). |
Q How many slides can I stain with a single kit?
Each UltiMapper kit can stain10 slides when running the assay on the Leica BOND RX. When performing the assay manually, each kit can stain 12+ slides.
Q What image analysis platforms can I use?
Image analysis can be performed on a number of different software platforms, including Indica Labs HALO, Visiopharm, ImageJ, and other platforms that can manage multiple fluorescent channels for analysis.
Q What imaging systems do I need to have?
UltiMapper kits are compatible with most fluorescent scanners. However, the imaging systems will need to have the appropriate filter sets including Cy7 capabilities.
Characterize regulatory T cells and cytotoxic T cells
The T-reg kit allows you to spatially map the activity and relationships between cytotoxic T cells, regulatory T cells, and T helper cells within the tumor context.
Determine whether the tumor is “hot” or “cold”
The PD-L1 immune infiltration kit enables co-localization of macrophages, cytotoxic T cells, tumor cells, and the underlying inhibitory or inflammatory mechanisms at play along the PD-L1 axis.
Determine whether T cells have the potential to mediate cell death
The T cell activation kit enables co-expression of proliferating cells, cytotoxic cells, tumor cells, and the underlying proliferative index and potential for T cell mediated death.
If you have specific research needs beyond our standard panel, we accommodate tailored design of custom panels. We are committed to delivering broader tumor immunology profiles, generating critical information to decipher complex mechanisms of cancer development and progression, and identifying relevant signatures of markers for research applications.
Our proprietary InSituPlex technology enables unsurpassed biomarker detection and analysis in tissue, with no compromise on level of multiplexing, throughput of sample staining and imaging, and with no requirement of dedicated instrumentation.
With speed and flexibility at heart, our Staining & Imaging services and Biomarker Programs offer highly customizable panels to include all your markers of interest.
Our proprietary InSituPlex technology enables unsurpassed biomarker detection and analysis in tissue, with no compromise on level of multiplexing, throughput of sample staining and imaging, and with no requirement of dedicated instrumentation.
With speed and flexibility at heart, our Biomarker Programs offer 5-Plex validated and highly customizable panels to include all your markers of interest.
Keith is a board-certified human anatomic pathologist with diverse achievements in research, drug/diagnostic development, and clinical investigation. Leading Ultivue’s Pathology and Biomarker Analytics team, he brings expertise in investigative pathology, multiplex microscopy and imaging, and digital pathology to our customers striving to realize the promise of personalized medicine. Most recently he was Senior Medical Director of Leica Biosystems, and prior to that he led and supported R&D, toxicology, biomarker, and clinical study teams in multiple therapeutic areas at Biogen and Novartis Institutes for BioMedical Research.
He earned a BS in Chemical Engineering from the University of Arizona, and MD and PhD in Molecular Biology from UCLA, where he discovered the molecular basis of DNA recognition by bHLH-PAS transcription factors. Following internship and residency in Anatomic Pathology and fellowships in Autopsy Pathology and Developmental Biology at Stanford, his research lab at UT Southwestern established the Naked cuticle (Nkd) gene family as critical feedback regulators of Wnt/-catenin signaling.
Richard is an experienced financial manager with more than thirty years of experience in finance, accounting, internal audit, financial planning and treasury roles. Richard was most recently the Vice President & Controller at Oxford Immunotec Global PLC where he was responsible for the global accounting, finance and treasury functions during their initial public offering, three acquisitions, a divestiture and sale of the company. Prior to Oxford Immunotec, he held Controller and other senior financial roles at several Medical Device and High Technology firms including Salient Surgical Technologies, Neurometrix and Teradyne.
Richard earned his BA in Economics from Trinity College, Hartford CT and his Master of Science in Management from MIT’s Sloan School of Management. He is a licensed Certified Public Accountant and a US Navy veteran.
Siobhan Desmond joined Ultivue in early 2021 as Head of People and Culture. Siobhan is responsible for leading the vision and development of the Human Resources strategy, including Talent Acquisition, Total Rewards, Leadership Development, Diversity and Engagement & Inclusion.
Siobhan is a business-focused, results oriented executive with over 20 years of experience in diverse industries. She is a leader who invests in designing & implementing successful HR strategies to create thriving, scalable cultures.
Siobhan holds a Master of Science in Human Resources and Adult Organizational Learning from Suffolk University as well as a Bachelor of Arts in English from Saint Anselm College. She has advised on boards, such as Veritas Community School and is passionate about life long learning.
Mike is a chemist/biologist with 15 years experience enabling innovative solutions in the biotechnology and diagnostics industries. He brings extensive experience in nucleic acid chemistry/enzymology, in situ biomolecule detection, multiplexed biomolecule analysis, and sequencing system development. Most recently he was Chief Scientist/Head of Genomics R&D at Beckman Coulter Life Sciences and previously consulted in varying capacities for both established and startup biotechnology companies.
Mike earned a BS in Microbiology and Cell Science and a PhD in Nucleic Acid Chemistry from the University of Florida, where he developed artificial genetic systems capable of replication and evolution. He was a NIH Ruth L. Kirschstein Postdoctoral Fellow at Harvard Medical School and a fellow at the Wyss Institute at Harvard where he developed multiplexed sequencing, in situ sequencing, and multiplexed synthetic biology technologies.
Barry Lynch has been Vice President of Sales since September 2020. He has significant leadership experience across a broad range of life science businesses, including histology, proteomics and diagnostics. Prior to joining Ultivue he was the Commercial Director (EMEA) with Advanced Cell Diagnostics. Barry began his career with Invitrogen in 1999 where he went on to lead commercial teams at the Europe and Asia Pacific regional level. He holds and honors degree in Biochemistry from the University of Dundee and a MSc in Biotechnology.
Mark Rees, PhD joined Ultivue’s executive team in January as Vice President of Corporate Development. Mark has 21+ years of leadership experience in Scientific Affairs and Business development within research and diagnostic markets. Most recently, Mark was instrumental in creating a diagnostic division for StatLab, launching a full portfolio of IHC reagents, automated staining platform as well as a patented reference standard control technology for tissue pathology. Previously Mark held leadership roles in commercial development, Scientific Affairs and R&D at Enzo Lifesciences, Leica Biosystems NA (Danaher) and Novocastra Laboratories.
He holds a PhD in Molecular Biology & Microbiology, MS in Industrial Microbiology and a BS (hons) in Biochemistry, graduating from Newcastle University Medical School, England UK
Sharon is Co-Founder, Partner of Northpond Ventures. Sharon is currently a board director at 908 Devices, Emulate, Isoplexis, Ultivue, and Vizgen. She was previously CFO of Sands Capital Management. Over her 15 years with Sands Capital, assets under management grew from $1.5 billion to $50 billion. Prior to Sands Capital, Sharon was a consultant at McKinsey & Company. Sharon has an MBA from Harvard Business School and a BA in Economics from Rice University. She is a CFA charterholder. Sharon is an advocate for financial literacy and her work has been featured nationally, including her two books, ON MY OWN TWO FEET: A Modern Girl’s Guide to Personal Finance and GET FINANCIALLY NAKED: How to Talk Money with your Honey.
Anna Pevzner is a Controller and Senior Director of Financial Planning & Analysis at Ultivue. Anna has nearly 20 years of finance experience in various positions across life sciences, technology, and advanced materials industries in public and venture capital-backed companies. Most recently Anna led finance function at Veloxint, where she supported fundraising and oversaw planning and accounting for the MIT-incubated advanced materials startup. Prior to Veloxint Anna was a Director of Financial Planning & Analysis at Syneos Health. Earlier in her career she held positions of increasing responsibility, including financial planning and analysis, manufacturing finance and accounting at Dolby Laboratories, Thermo Fisher Scientific and Pelephone Communications.
Anna holds an MBA degree from Carnegie Mellon University, Tepper School of Business and BA degree in Economics from Ben-Gurion University of the Negev.